Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Qilu Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Qilu Pharmaceutical Co (Global / Institutional) sponsors 115 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 71 active protocols (29 recruiting now), 13 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.9%
Median Closed Enrollment vs National (145 pts)168 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Qilu Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)115
Active Pipeline (Recruiting Now)71 (29)
Completed vs Stopped Early13 / 1 (0.9%)
Median Closed Actual Enrollment168 participants
Physical Hospital Site Disclosure99.6% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Qilu Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong8
Beijing Cancer HospitalBeijing, Beijing Municipality6
Shanghai East HospitalShanghai6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Qilu Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06406205A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus NephritisPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Qilu Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI